瀏覽量: 218
- 產(chǎn)品名稱: Research Grade Dupilumab ( 度匹魯單抗 )
- 產(chǎn)品貨號(hào): CSD00304
- 貨期: 現(xiàn)貨
- 價(jià)格與訂購(gòu): 2480
- 數(shù)量:
- 規(guī)格: 100μg
- 產(chǎn)品信息
- 如何訂購(gòu)
貨號(hào)(Catalog No.)
CSD00304
通用名INN
Dupilumab
純度(Purity)
>95%
濃度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
內(nèi)毒素(Endotoxin level)
Please contact with the lab for this information.
產(chǎn)品描述(Description)
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
別名(Alternative names)
CD124,REGN668,SAR231893
靶點(diǎn);物種(Specificity target name;species)
IL4R/CD124[Homo sapiens]
活性研究(體外/體內(nèi)研究)(Activity in vitro)
Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17–related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab.
Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR. The changes in other critical epidermal alterations in severe atopic dermatitis (AD) skin are also measured, including significant increases in claudin and lipid product levels with 300 mg of Dupilumab. A trend of dose-dependent increases in expression of differentiation genes (LOR and FLG) is observed after adjusting for suppression of epidermal hyperplasia, as demonstrated by K16 reductions with Dupilumab.
種類(Species)
Homo sapiens
受體鑒定(Receptor identification)
IgG4-kappa
CAS
1190264-60-8
存儲(chǔ)條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .